Primecap Management’s Edwards Lifesciences EW Stock Holding History

Primecap Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$308M	Sell	3,408,291 -14,500	-0.4%	-$1.21M	0.18%	97
2026 Q1	$274M	Buy	3,422,791 +4,000	+0.1%	+$330K	0.22%	89
2025 Q4	$291M	Sell	3,418,791 -104,500	-3%	-$8.58M	0.22%	90
2025 Q3	$274M	Buy	3,523,291 +76,400	+2%	+$5.97M	0.21%	91
2025 Q2	$270M	Buy	3,446,891 +1,147,291	+50%	+$85.6M	0.21%	87
2025 Q1	$167M	Buy	2,299,600 +256,100	+13%	+$18.3M	0.14%	108
2024 Q4	$151M	Buy	2,043,500 +258,800	+15%	+$18.1M	0.12%	118
2024 Q3	$118M	Sell	1,784,700 -26,300	-1%	-$1.91M	0.09%	130
2024 Q2	$167M	Sell	1,811,000 -90,000	-5%	-$7.97M	0.12%	108
2024 Q1	$182M	Hold	1,901,000	–	–	0.14%	101
2023 Q4	$145M	Sell	1,901,000 -35,000	-2%	-$2.44M	0.11%	112
2023 Q3	$134M	Hold	1,936,000	–	–	0.11%	114
2023 Q2	$183M	Hold	1,936,000	–	–	0.15%	105
2023 Q1	$160M	Sell	1,936,000 -30,000	-2%	-$2.36M	0.14%	108
2022 Q4	$147M	Sell	1,966,000 -90,300	-4%	-$6.96M	0.13%	112
2022 Q3	$170M	Hold	2,056,300	–	–	0.16%	105
2022 Q2	$196M	Sell	2,056,300 -59,200	-3%	-$6.13M	0.17%	96
2022 Q1	$249M	Sell	2,115,500 -72,800	-3%	-$8.17M	0.19%	97
2021 Q4	$283M	Sell	2,188,300 -84,100	-4%	-$9.81M	0.2%	97
2021 Q3	$257M	Sell	2,272,400 -153,100	-6%	-$17.5M	0.18%	102
2021 Q2	$251M	Hold	2,425,500	–	–	0.17%	106
2021 Q1	$203M	Buy	2,425,500 +105,000	+5%	+$8.88M	0.14%	116
2020 Q4	$212M	Hold	2,320,500	–	–	0.16%	110
2020 Q3	$185M	Hold	2,320,500	–	–	0.15%	111
2020 Q2	$160M	Hold	2,320,500	–	–	0.14%	118
2020 Q1	$146M	Buy	2,320,500 +715,500	+45%	+$51.6M	0.14%	113
2019 Q4	$125M	Hold	1,605,000	–	–	0.09%	132
2019 Q3	$118M	Hold	1,605,000	–	–	0.09%	135
2019 Q2	$98.8M	Hold	1,605,000	–	–	0.07%	145
2019 Q1	$102M	Hold	1,605,000	–	–	0.08%	145
2018 Q4	$81.9M	Hold	1,605,000	–	–	0.07%	147
2018 Q3	$93.1M	Hold	1,605,000	–	–	0.06%	148
2018 Q2	$77.9M	Hold	1,605,000	–	–	0.06%	149
2018 Q1	$74.6M	Buy	1,605,000 +105,000	+7%	+$4.56M	0.06%	153
2017 Q4	$56.4M	Sell	1,500,000 -76,200	-5%	-$2.8M	0.04%	167
2017 Q3	$57.4M	Sell	1,576,200 -103,800	-6%	-$3.96M	0.05%	167
2017 Q2	$66.2M	Hold	1,680,000	–	–	0.06%	162
2017 Q1	$52.7M	Hold	1,680,000	–	–	0.05%	163
2016 Q4	$52.5M	Hold	1,680,000	–	–	0.05%	156
2016 Q3	$67.5M	Hold	1,680,000	–	–	0.07%	147
2016 Q2	$55.8M	Hold	1,680,000	–	–	0.06%	156
2016 Q1	$49.4M	Hold	1,680,000	–	–	0.05%	162
2015 Q4	$44.2M	Hold	1,680,000	–	–	0.05%	174
2015 Q3	$39.8M	Hold	1,680,000	–	–	0.04%	178
2015 Q2	$39.9M	Hold	1,680,000	–	–	0.04%	181
2015 Q1	$39.9M	Hold	1,680,000	–	–	0.04%	179
2014 Q4	$35.7M	Hold	1,680,000	–	–	0.04%	183
2014 Q3	$28.6M	Hold	1,680,000	–	–	0.03%	185
2014 Q2	$24M	Hold	1,680,000	–	–	0.03%	185
2014 Q1	$20.8M	Hold	1,680,000	–	–	0.02%	189
2013 Q4	$18.4M	Hold	1,680,000	–	–	0.02%	196
2013 Q3	$19.5M	Hold	1,680,000	–	–	0.03%	193
2013 Q2	$18.8M	Buy	+1,680,000	New	+$19.9M	0.03%	190

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Primecap Management's EW Position: Q2 2026 in Review

Primecap Management reduced its Edwards Lifesciences (EW) stake by 0.42% in Q2 2026, selling an estimated $1.21M and leaving 3,408,291 shares worth $308M. The position accounts for 0.18% of the portfolio, ranked #97.

Primecap Management first reported a position in EW in Q2 2013 and has held it in 53 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Primecap Management held 3,408,291 shares of Edwards Lifesciences worth $308M as of Q2 2026.
Primecap Management sold 14,500 Edwards Lifesciences shares in Q2 2026, an estimated $1.21M.
Edwards Lifesciences made up 0.18% of Primecap Management's portfolio in Q2 2026, its #97 holding.
Primecap Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.